8 news items
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
ARCT
15 May 24
types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
ARCT
8 May 24
' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
ARCT
25 Apr 24
platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self
19eltk99gbjgl10hdzih1ttvhykuweare045va3wv7rkql6zn9bts
ARCT
7 Mar 24
can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self
st10wbv qp258ihkf8pt1n8n5y11wrav40dwxhj7
ARCT
26 Feb 24
messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies
ejsbbq24trw0036u
ARCT
22 Feb 24
messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies
- Prev
- 1
- Next